[Skip to Content]
[Skip to Content Landing]
Article
June 19, 1987

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

Author Affiliations

From the Atherosclerosis Research Institute, the Department of Medicine (Drs Blankenhorn, Sanmarco, and Cashin-Hemphill), and the Department of Preventive Medicine (Drs Nessim and Azen), University of Southern California School of Medicine, Los Angeles.

From the Atherosclerosis Research Institute, the Department of Medicine (Drs Blankenhorn, Sanmarco, and Cashin-Hemphill), and the Department of Preventive Medicine (Drs Nessim and Azen), University of Southern California School of Medicine, Los Angeles.

JAMA. 1987;257(23):3233-3240. doi:10.1001/jama.1987.03390230069027
Abstract

The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery. During two years of treatment there was a 26% reduction in total plasma cholesterol, a 43% reduction in low-density lipoprotein cholesterol, plus a simultaneous 37% elevation of high-density lipoprotein cholesterol. This resulted in a significant reduction in the average number of lesions per subject that progressed (P<.03) and the percentage of subjects with new atheroma formation (P<.03) in native coronary arteries. Also, the percentage of subjects with new lesions (P<.04) or any adverse change in bypass grafts (P<.03) was significantly reduced. Deterioration in overall coronary status was significantly less in drug-treated subjects than placebo-treated subjects (P<.001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated (P =.002).

(JAMA 1987;257:3233-3240)

×